GB201322602D0 - Pharmaceutical compounds - Google Patents
Pharmaceutical compoundsInfo
- Publication number
- GB201322602D0 GB201322602D0 GBGB1322602.2A GB201322602A GB201322602D0 GB 201322602 D0 GB201322602 D0 GB 201322602D0 GB 201322602 A GB201322602 A GB 201322602A GB 201322602 D0 GB201322602 D0 GB 201322602D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- pharmaceutical compounds
- pharmaceutical
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (28)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1322602.2A GB201322602D0 (en) | 2013-12-19 | 2013-12-19 | Pharmaceutical compounds |
| NO14815843A NO3083625T3 (OSRAM) | 2013-12-19 | 2014-12-19 | |
| PCT/GB2014/053793 WO2015092431A1 (en) | 2013-12-19 | 2014-12-19 | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors |
| BR112016014151-2A BR112016014151B1 (pt) | 2013-12-19 | 2014-12-19 | Pirirmidopirimidinonas úteis como inibidores de quinases wee-1 |
| LTEP14815843.9T LT3083625T (lt) | 2013-12-19 | 2014-12-19 | Pirimidopirimidinonai, tinkami naudoti kaip wee-1 kinazės inhibitoriai |
| EP14815843.9A EP3083625B1 (en) | 2013-12-19 | 2014-12-19 | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors |
| HUE14815843A HUE037908T2 (hu) | 2013-12-19 | 2014-12-19 | Pirimodopirimidononok mint WEE-1 kináz inhibitorok |
| CA2933755A CA2933755C (en) | 2013-12-19 | 2014-12-19 | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors |
| PL14815843T PL3083625T3 (pl) | 2013-12-19 | 2014-12-19 | Pirymidopirymidynony użyteczne jako inhibitory kinazy wee-1 |
| HRP20180080TT HRP20180080T1 (hr) | 2013-12-19 | 2014-12-19 | Pirimidopirimidinoni korisni kao inhibitori wee-1 kinaze |
| NZ720178A NZ720178A (en) | 2013-12-19 | 2014-12-19 | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors |
| RS20171338A RS56731B1 (sr) | 2013-12-19 | 2014-12-19 | Pirimidopirimidinoni korisni kao inhibitori wee-1 kinaze |
| CN201480069437.9A CN105829315B (zh) | 2013-12-19 | 2014-12-19 | 可用作Wee-1激酶抑制剂的嘧啶并嘧啶酮类 |
| JP2016541294A JP6437559B2 (ja) | 2013-12-19 | 2014-12-19 | Ｗｅｅ−１キナーゼ阻害剤として有用なピリミドピリミジノン |
| KR1020167019551A KR102405462B1 (ko) | 2013-12-19 | 2014-12-19 | Wee-1 카이네이즈 억제제로 유용한 피리미도피리미디논 |
| SI201430580T SI3083625T1 (en) | 2013-12-19 | 2014-12-19 | Pyrimidopyrimidinones, useful as Wee-1 kinase inhibitors |
| SM20180020T SMT201800020T1 (it) | 2013-12-19 | 2014-12-19 | Pirimidopirimidinoni utili come inibitori della chinasi wee-1 |
| US15/105,869 US9850247B2 (en) | 2013-12-19 | 2014-12-19 | Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors |
| ES14815843.9T ES2650013T3 (es) | 2013-12-19 | 2014-12-19 | Pirimidopirimidinonas útiles como inhibidores de la quinasa Wee-1 |
| AU2014369457A AU2014369457B2 (en) | 2013-12-19 | 2014-12-19 | Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors |
| MX2016007801A MX371108B (es) | 2013-12-19 | 2014-12-19 | Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa. |
| PT148158439T PT3083625T (pt) | 2013-12-19 | 2014-12-19 | Pirimidopirimidinonas úteis como inibidores da cinase wee-1 |
| DK14815843.9T DK3083625T3 (en) | 2013-12-19 | 2014-12-19 | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors |
| RU2016123363A RU2691105C1 (ru) | 2013-12-19 | 2014-12-19 | Лекарственные соединения |
| SG11201603814TA SG11201603814TA (en) | 2013-12-19 | 2014-12-19 | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors |
| ZA2016/03337A ZA201603337B (en) | 2013-12-19 | 2016-05-17 | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors |
| IL245672A IL245672B (en) | 2013-12-19 | 2016-05-17 | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors |
| CY20181100041T CY1120035T1 (el) | 2013-12-19 | 2018-01-15 | Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασης |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1322602.2A GB201322602D0 (en) | 2013-12-19 | 2013-12-19 | Pharmaceutical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201322602D0 true GB201322602D0 (en) | 2014-02-05 |
Family
ID=50071157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1322602.2A Ceased GB201322602D0 (en) | 2013-12-19 | 2013-12-19 | Pharmaceutical compounds |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9850247B2 (OSRAM) |
| EP (1) | EP3083625B1 (OSRAM) |
| JP (1) | JP6437559B2 (OSRAM) |
| KR (1) | KR102405462B1 (OSRAM) |
| CN (1) | CN105829315B (OSRAM) |
| AU (1) | AU2014369457B2 (OSRAM) |
| BR (1) | BR112016014151B1 (OSRAM) |
| CA (1) | CA2933755C (OSRAM) |
| CY (1) | CY1120035T1 (OSRAM) |
| DK (1) | DK3083625T3 (OSRAM) |
| ES (1) | ES2650013T3 (OSRAM) |
| GB (1) | GB201322602D0 (OSRAM) |
| HR (1) | HRP20180080T1 (OSRAM) |
| HU (1) | HUE037908T2 (OSRAM) |
| IL (1) | IL245672B (OSRAM) |
| LT (1) | LT3083625T (OSRAM) |
| MX (1) | MX371108B (OSRAM) |
| NO (1) | NO3083625T3 (OSRAM) |
| NZ (1) | NZ720178A (OSRAM) |
| PL (1) | PL3083625T3 (OSRAM) |
| PT (1) | PT3083625T (OSRAM) |
| RS (1) | RS56731B1 (OSRAM) |
| RU (1) | RU2691105C1 (OSRAM) |
| SG (1) | SG11201603814TA (OSRAM) |
| SI (1) | SI3083625T1 (OSRAM) |
| SM (1) | SMT201800020T1 (OSRAM) |
| WO (1) | WO2015092431A1 (OSRAM) |
| ZA (1) | ZA201603337B (OSRAM) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108137593B (zh) * | 2015-04-21 | 2021-01-05 | 上海交通大学医学院附属瑞金医院 | 蛋白激酶抑制剂的制备和用途 |
| CA3003737C (en) | 2015-11-01 | 2021-09-14 | The Regents Of The University Of Colorado, A Body Corporate | Wee1 kinase inhibitors and methods of making and using the same |
| JP7240784B2 (ja) * | 2016-11-16 | 2023-03-16 | 上海瑛派▲薬▼▲業▼有限公司 | ８，９－ジヒドロイミダゾール［１，２－ａ］ピリミド［５，４－ｅ］ピリミジン－５（６Ｈ）－ケトン類化合物 |
| WO2018124001A1 (ja) | 2016-12-27 | 2018-07-05 | 国立研究開発法人理化学研究所 | Ｂｍｐシグナル阻害化合物 |
| ES2902050T3 (es) | 2017-01-23 | 2022-03-24 | Shijiazhuang Sagacity New Drug Dev Co Ltd | Derivado 1,2-dihidro-3H-pirazolo[3,4-D]pirimidin-3-ona como inhibidor de Wee1 |
| GB201703881D0 (en) | 2017-03-10 | 2017-04-26 | Almac Discovery Ltd | Pharmaceutical compounds |
| US20200108074A1 (en) | 2017-03-31 | 2020-04-09 | Seattle Genetics, Inc. | Combinations of chk1- and wee1- inhibitors |
| WO2019011228A1 (zh) * | 2017-07-10 | 2019-01-17 | 上海瑛派药业有限公司 | 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用 |
| WO2019037678A1 (zh) * | 2017-08-24 | 2019-02-28 | 上海迪诺医药科技有限公司 | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 |
| WO2019074981A1 (en) | 2017-10-09 | 2019-04-18 | GiraFpharma LLC | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| WO2019074979A1 (en) | 2017-10-09 | 2019-04-18 | Girafpharma, Llc | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| PT3712150T (pt) | 2017-11-01 | 2024-08-22 | Wuxi Biocity Biopharmaceutics Co Ltd | Composto macrocíclico que serve como inibidor wee1 e aplicações do mesmo |
| CA3088997A1 (en) | 2018-02-28 | 2019-09-06 | The Regents Of The University Of Colorado, A Body Corporate | Wee1 kinase inhibitors and methods of treating cancer using the same |
| WO2020063788A1 (zh) * | 2018-09-27 | 2020-04-02 | 贝达药业股份有限公司 | Fgfr4抑制剂及其应用 |
| JP7481336B2 (ja) | 2018-10-26 | 2024-05-10 | ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド | Ｗｅｅ１阻害剤としてのピリミドピラゾロン類誘導体及びその使用 |
| US20230065740A1 (en) | 2018-12-28 | 2023-03-02 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
| JP2022528047A (ja) | 2019-03-22 | 2022-06-08 | ショウヤオ ホールディングス（ベイジン） カンパニー， リミテッド | Ｗｅｅ１阻害剤、その製造および用途 |
| EP3952878A4 (en) * | 2019-04-09 | 2023-01-04 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND THEIR USES |
| US20220162229A1 (en) * | 2019-04-09 | 2022-05-26 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| WO2020210375A1 (en) | 2019-04-09 | 2020-10-15 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| US12291536B2 (en) | 2019-04-30 | 2025-05-06 | Wuxi Biocity Biopharmaceutics Co., Ltd. | Crystal form of Wee1 inhibitor compound and use thereof |
| CN112142763B (zh) * | 2019-06-28 | 2024-01-26 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
| US12522607B2 (en) | 2020-06-17 | 2026-01-13 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Substituted pyrazolo[3,4-d]pyrimidines as wee-1 inhibitors |
| US20230416247A1 (en) * | 2020-10-01 | 2023-12-28 | University Of Washington | Drug-like molecules and methods for the therapeutic targeting of microrna-21 |
| US12551584B1 (en) | 2020-12-07 | 2026-02-17 | Actinium Pharmaceuticals, Inc. | Lewis Y radioimmunotherapy for the treatment of cancer |
| CA3202328A1 (en) * | 2020-12-18 | 2022-06-23 | Jie GUANG | Chemical compounds useful for inhibiting nav1.8 voltage-gated sodium channels and treating nav1.8 mediated diseases |
| TW202239409A (zh) * | 2020-12-18 | 2022-10-16 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 化合物 |
| EP4332104A4 (en) | 2021-04-30 | 2025-04-16 | Wigen Biomedicine Technology (Shanghai) Co., Ltd. | Fused ring compound as a WEE-1 inhibitor, as well as production process and use thereof |
| WO2022270994A1 (ko) | 2021-06-25 | 2022-12-29 | 한국화학연구원 | 유비퀴틴 프로테오좀 경로를 통해 비티케이 분해작용을 가지는 신규한 이작용성 헤테로사이클릭 화합물과 이의 용도 |
| CN116462687B (zh) | 2022-01-18 | 2025-01-07 | 江苏天士力帝益药业有限公司 | Wee1抑制剂及其制备和用途 |
| CN116836184B (zh) * | 2022-03-25 | 2025-07-25 | 药雅科技(上海)有限公司 | Wee1激酶抑制剂的制备及其应用 |
| WO2023217201A2 (zh) * | 2022-05-10 | 2023-11-16 | 杭州德睿智药科技有限公司 | 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用 |
| CN117402162A (zh) | 2022-07-13 | 2024-01-16 | 江苏天士力帝益药业有限公司 | Wee1抑制剂及其制备和用途 |
| WO2025101691A1 (en) | 2023-11-08 | 2025-05-15 | Exelixis, Inc. | Methods for treating cancer using compounds that inhibit pkmyt1 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| WO2005090344A1 (en) | 2004-03-15 | 2005-09-29 | F. Hoffmann-La Roche Ag | Novel dichloro-phenyl-pyrido [2,3-d] pyrimidine derivates, their manufacture and use as pharmaceutical agents |
| FR2896246B1 (fr) | 2006-01-13 | 2008-08-15 | Sanofi Aventis Sa | Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique. |
| PE20080695A1 (es) | 2006-04-27 | 2008-06-28 | Banyu Pharma Co Ltd | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel |
| US8198281B2 (en) | 2007-04-25 | 2012-06-12 | Merck Sharp & Dohme Corp. | Crystalline forms of dihydropyrazolopyrimidinone |
| CA2689429C (en) | 2007-06-15 | 2012-08-21 | Banyu Pharmaceutical Co., Ltd. | Bicycloaniline derivatives |
| US8329711B2 (en) | 2007-10-23 | 2012-12-11 | Msd K.K. | Pyridone-substituted-dihydropyrazolopyrimidinone derivative |
| CA2745970A1 (en) | 2008-12-12 | 2010-06-17 | Msd K.K. | Dihydropyrimidopyrimidine derivative |
| US8575179B2 (en) * | 2008-12-12 | 2013-11-05 | Msd K.K. | Dihydropyrazolopyrimidinone derivatives |
| KR101861883B1 (ko) * | 2010-12-06 | 2018-05-28 | 글락소 그룹 리미티드 | Lp-PLA₂에 의해 매개되는 질환 또는 상태의 치료에 사용하기 위한 피리미디논 화합물 |
| AR084515A1 (es) * | 2010-12-22 | 2013-05-22 | Merz Pharma Gmbh & Co Kgaa | Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras |
| TWI532742B (zh) | 2011-02-28 | 2016-05-11 | 艾伯維有限公司 | 激酶之三環抑制劑 |
| US8716297B2 (en) | 2011-07-15 | 2014-05-06 | Abbvie Inc. | Chemical entities to be used for Wee1 inhibition for the treatment of cancer |
| US8796289B2 (en) * | 2011-07-19 | 2014-08-05 | Abbvie Inc. | Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases |
| CA2851640A1 (en) | 2011-10-20 | 2013-04-25 | Abbvie Inc. | Pyridopyrimidinone inhibitors of kinases |
| MX2014010176A (es) | 2012-02-23 | 2014-11-10 | Abbvie Inc | Inhibidores de cinasas de piridopirimidinona. |
| CN102816164A (zh) * | 2012-08-31 | 2012-12-12 | 北京理工大学 | 一种合成7-氨基-2,3-二氢嘧啶[4,5-d]嘧啶-4(1H)-酮的方法 |
-
2013
- 2013-12-19 GB GBGB1322602.2A patent/GB201322602D0/en not_active Ceased
-
2014
- 2014-12-19 SI SI201430580T patent/SI3083625T1/en unknown
- 2014-12-19 US US15/105,869 patent/US9850247B2/en active Active
- 2014-12-19 LT LTEP14815843.9T patent/LT3083625T/lt unknown
- 2014-12-19 SM SM20180020T patent/SMT201800020T1/it unknown
- 2014-12-19 HU HUE14815843A patent/HUE037908T2/hu unknown
- 2014-12-19 CN CN201480069437.9A patent/CN105829315B/zh active Active
- 2014-12-19 HR HRP20180080TT patent/HRP20180080T1/hr unknown
- 2014-12-19 BR BR112016014151-2A patent/BR112016014151B1/pt active IP Right Grant
- 2014-12-19 MX MX2016007801A patent/MX371108B/es active IP Right Grant
- 2014-12-19 SG SG11201603814TA patent/SG11201603814TA/en unknown
- 2014-12-19 ES ES14815843.9T patent/ES2650013T3/es active Active
- 2014-12-19 CA CA2933755A patent/CA2933755C/en active Active
- 2014-12-19 WO PCT/GB2014/053793 patent/WO2015092431A1/en not_active Ceased
- 2014-12-19 PL PL14815843T patent/PL3083625T3/pl unknown
- 2014-12-19 RU RU2016123363A patent/RU2691105C1/ru active
- 2014-12-19 NZ NZ720178A patent/NZ720178A/en unknown
- 2014-12-19 AU AU2014369457A patent/AU2014369457B2/en active Active
- 2014-12-19 DK DK14815843.9T patent/DK3083625T3/en active
- 2014-12-19 RS RS20171338A patent/RS56731B1/sr unknown
- 2014-12-19 KR KR1020167019551A patent/KR102405462B1/ko active Active
- 2014-12-19 JP JP2016541294A patent/JP6437559B2/ja active Active
- 2014-12-19 PT PT148158439T patent/PT3083625T/pt unknown
- 2014-12-19 EP EP14815843.9A patent/EP3083625B1/en active Active
- 2014-12-19 NO NO14815843A patent/NO3083625T3/no unknown
-
2016
- 2016-05-17 ZA ZA2016/03337A patent/ZA201603337B/en unknown
- 2016-05-17 IL IL245672A patent/IL245672B/en unknown
-
2018
- 2018-01-15 CY CY20181100041T patent/CY1120035T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201306610D0 (en) | Pharmaceutical compounds | |
| IL240846A0 (en) | drug combination | |
| AP2015008713A0 (en) | Tetrahydropyrrolothiazine compounds | |
| GB201302927D0 (en) | Compounds | |
| ZA201602047B (en) | Pharmaceutical compounds | |
| AP3850A (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| SG11201601477VA (en) | Pharmaceutical composition | |
| ZA201600027B (en) | Pharmaceutical preparation | |
| GB201312386D0 (en) | Pharmaceutical compounds | |
| EP2948457A4 (en) | COMPOUNDS | |
| GB201306794D0 (en) | Compounds | |
| IL244365A0 (en) | pharmaceutical preparation | |
| GB201317166D0 (en) | Pharmaceutical compounds | |
| GB201316780D0 (en) | Pharmaceutical compounds | |
| GB201316791D0 (en) | Pharmaceutical Compounds | |
| GB201315733D0 (en) | Pharmaceutical compounds | |
| GB201315734D0 (en) | Pharmaceutical compounds | |
| GB201312464D0 (en) | Pharmaceutical compounds | |
| GB201308780D0 (en) | Pharmaceutical compounds | |
| GB201308782D0 (en) | Pharmaceutical compounds | |
| GB201308781D0 (en) | Pharmaceutical compounds | |
| GB201321316D0 (en) | Pharmaceutical Compound | |
| GB201309405D0 (en) | Pharmaceutical compound | |
| GB201316662D0 (en) | Pharmaceutical Combination | |
| ZA201506465B (en) | Pharmaceutical preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |